You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

199 Results
Guidelines and Advice
Status: Current
ID: GL-C50-34
Aug 2017
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Adjuvant, Palliative
Aug 2017
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Aug 2017
Regimen
Cancer Type:
Central Nervous System
Intent: Palliative
Aug 2017
Guidelines and Advice
Status: Current
ID: GL-C50-33
Version: 1
Aug 2017
Drug
Other Name(s): Lynparza®
Jan 2025
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    fulvestrant
Jan 2025
Drug
Other Name(s): Padcev®
Jan 2025
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Funding:
New Drug Funding Program
    Enfortumab Vedotin - Previously Treated Advanced or Metastatic Urothelial Cancer
Jan 2025
Drug
Other Name(s): Columvi®
Jan 2025

Pages